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1. Introduction 
Over the last few years, the survival of cystic fibrosis (CF) patients has increased markedly. 
This is attributed to earlier diagnoses of the disease, the improvement of patient care 
involving multidisciplinary teams and more effective therapeutic options.  
The therapeutic requirements of patients with CF are highly complex. Many patients require 
continuous care at home with many prophylactic medications, such as nebulised or oral 
antibiotics, pancreatic enzymes, mucolytic agents, vitamin and nutritional supplements as 
well as daily physiotherapy and a healthy lifestyle with adequate nutrition and exercise. 
These treatments are intensified and become more complicated during the exacerbation of 
the disease. Throughout its evolution, other pathologies associated with CF may also occur 
which require extra treatment regimens.  
The complexity of the therapeutic requirements of these patients has added to their 
longevity. The life-long duration of the treatment and their complexity, have been pointed 
to as the main determinants of therapeutic adherence. Preventative management and 
symptomatic treatment are introduced in early childhood for most people with CF, and so 
management and treatment routines have been a daily concern for most adults for many 
years. (Kettler et al.,  2002; Modi et al., 2006).  
All of these difficulties have been identified as determinants of adherence and they are 
shared with the patients of other chronic diseases. Accordingly, the compliance rate in CF 
cases is very similar as that of the other chronically ill. In 1979, Sackett and Snow reviewed 
537 studies on adherence in chronic disease cases, indicating that the range of adherence for 
long term preventative regimens was 33-94% with a mean adherence rate of 57% and for 
long term treatment the range was 41-61% with a mean adherence rate of 54%. Later, poor 
compliance with medical advice and prescribed treatments in the chronically ill in general is 
well-documented in the literature, and adherence rarely exceeds 80% and more often it is 
between 30% and 70%. (Abbott et al., 1996; Conway et al., 1996; Daniels et al., 2011; Kettler 
et al., 2002; Michaud et al., 1991; Modi et al., 2006). 
2. The definition of adherence and compliance 
The term compliance is applied when patients follow closely and correctly all the 
therapeutic indications prescribed by physicians. So, the definition of compliance is “the 
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extent to which patients are obedient and follow the instructions, proscriptions and 
prescriptions of health professionals”.  We talk about adherence meaning the extent to 
which the patient responds to these indications, taking them and ’endorsing’ them as his 
own.  This refers not only to medication, but it also includes non-pharmacological measures, 
such as hygiene, diet controls, etc. (Kettler et al., 2002, as cited in Meichenbaum & Turk, 
1987). So, adherence is defined as an “active, voluntary, collaborative involvement of the 
patient in a mutually acceptable course of behaviour to produce a desired preventative or 
therapeutic result”. However, both terms receive general use and so are treated indifferently 
in the literature. No doubt the results of adherence are influenced by the definition adopted. 
Lots of different classifications of adherence – and extent of this has been described – have 
been assessed from different points of view. Some authors have suggested that patients 
should be described as fully-adherent, partially-adherent or non-compliant (Lask, 1994). 
Koocher differentiates the term non-compliant into three groups: those who have an 
inadequate understanding of the disease, those who present a psychological resistance to 
disease, and those who – when properly educated – choose not to be compliant (Koocher et 
al., 1990).  
On the other hand, it has been found to be very difficult to classify an individual as 
compliant. Studies have found that despite compliance, significantly less than 100% could 
achieve the desired health outcomes (Kettler et al., 2002). However, the cut off point at 
which they would stop objectifying favourable results and should promote greater 
compliance is very difficult to define. 
Poor adherence can lead to more rapid disease progression. (Abbott et al., 2001; 
Patterson et al., 1993). Nonetheless, there are studies that reject the existence of a 
conclusive association between poor compliance and disease progression (Abbott et al., 
1994). However, a lack of compliance may increase the number of consultations and 
hospital admissions with a consequent increase in health spending. In addition, it may 
hinder the knowledge of the effectiveness of treatments. On the other hand, it is believed 
that total adherence may not be necessary, as the complete fulfilment of all of the 
components of a treatment does not guarantee good health. (Abbott et al., 2001). It is 
known that a patient with poor compliance may stay well, perhaps because of individual 
responses to different treatments. It is reasonable, therefore, be able to find a balance 
between the two sides, but is not an easy task for the specialist in relation to these 
patients. 
3. The measurement of adherence  
The measure of treatment adherence is not an easy task. We must find a balance between the 
errors obtained using certain procedures – such as personal interview – and the difficulty in 
performing other more objective technical procedures. 
The methods most commonly used to study adherence in patients with CF include: 
3.1 Personal interview  
The most frequently used method is to ask directly or take a survey of the patient as to 
whether the treatment takes place and to what extent it does so. However, patients often 
tend to overestimate their compliance (Abbott et al., 1996; Conway et al., 1996, Kettler et al., 
2002) and frequently this does not reflect the opinion of the specialist. This data can be 
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compared by asking the opinion of the medical team responsible for the patient or else their 
family. Although this is the easiest and most accessible system for assessing adherence to all 
kinds of treatments, it cannot be denied that the results are not entirely objective.  
3.2 Therapeutic response 
Using this method of measuring adherence in such a complex disease as CF and the many 
variants of treatment can lead to errors. In particular, knowledge of the desired effect 
achieved by taking a certain drug is almost impossible given the significant interaction 
between the different treatments. 
3.3 Serum or urinary excretion of drugs or their metabolites 
The first thing to note is that this is an invasive method and as such it is highly 
uncomfortable for the patient, who would have to undergo a large number of extractions in 
order to verify their genuine compliance. This problem is compounded by the 
pharmacokinetic variations of the substances studied, and it allows the analysis of only 
certain medications and reports only those drugs that have been recently consumed by the 
patient. 
3.4 Monitoring with electronics, such as aerosol dispensers or nebulisers, that record 
the date and time of each dispensation 
This data would be periodically downloaded for analysis so as to give an idea of 
adherence. Amongst its advantages it is worth noting that it allows us to guess the 
behaviour of patients, it is non-invasive, and it allows the collection of data over a long 
period of time without the patient having to attend hospital. On the other hand, this type 
of monitoring has its limitations. With its high cost we must also add the fact that data 
provide information about the use of a medication removed from dispenser. However, it 
is reasonable to assume that most patients who make the effort to remove medication 
from the dispenser in the prescribed way will also consume the medication. This 
technology is limited when used for evaluating physical therapy, and it gives no 
information on adherence to such treatment regimens as exercise or diet (Kettler et al., 
2002; McNamara et al., 2009; Modi et al., 2006). 
4. Predictors of compliance 
Once the degree of compliance of a patient is measured, it is interesting to know the reasons 
for why compliance might not be adequate and identify the motivations for good adherence. 
Understanding the factors that may be related to adherence will enable us to act on them to 
some degree and so improve compliance and impact upon the course of the disease. 
Described below are the factors that have often been studied as predictors of compliance in 
the literature. 
4.1 The relationship between the patient and health professionals  
In a chronic disease with a complex treatment such as CF, the relationship of patients with 
their health professionals is very important. This can have a positive or negative impact on 
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compliance, and so it should foster an environment of trust that allows for good 
communications between them. Numerous studies have shown that those who believe that 
it is important to follow your doctor's instructions and those who have confidence in the 
benefits of their treatment are more compliant. (Abbott et al., 2001; Patterson et al., 1993) The 
level of adherence has been linked with the knowledge of the specifics associated with 
prescribed medical treatments. Therefore, the physician must strive to convey adequate 
information which is detailed yet easy to understand. After all, in many cases the patient has 
not properly understood the reason for each prescription, as made clear by the fact that 12%-
32% of mothers do not fully understand the medical advice concerning their child (Ievers et 
al., 1999). 
Such appropriate information must convince patients that their actions when performing 
the treatment will impact on the course of their disease. The fact of involving the patient will 
give us with the ability to schedule a treatment plan together with them and which allows 
us to improve adherence. To do this, we must recognise that there is no single treatment for 
all patients and it should be individualised and simplified wherever possible. 
 Moreover, the maintenance of adequate adherence to prescribed treatments is very 
important for care monitoring and the provision of adequate supervision, and we should 
always try not to judge and accept that a lack of enforcement is, to a certain extent, normal 
with this type of disease (Conway et al., 1996; Lask et al., 1994).  
4.2 The severity of the disease 
The perception of the severity of the disease differs between doctors and patients. From the 
doctor’s point of view, the patients underestimate the severity of their disease and 
overestimate their care.  
Some authors suggest that adherence is worse amongst those patients with more severe 
cases due to a lack of positive reinforcement in that they do not notice any beneficial effect 
resulting from adherence to their treatment (Kettler et al., 2002). However, the severity of 
the disease has often been evaluated as a possible predictor of adherence in CF cases with 
conflicting results (Abbott et al., 1994, 1996, 2001; Conway et al., 1996; Gudas et al., 1991; 
Kettler et al., 2002). 
4.3 Social and family relationships 
It is very important that patients with CF receive good socio-familial support. Strong family 
cohesion and adequate social support have been associated with better adherence to 
treatment. A special importance is attached to the family in the care of patients during 
childhood, where the burden of treatment compliance during this time of life is maintained 
by the parents (Battistini et al., 1998; Eddy et al., 1998; Foster et al., 2001; Moise et al., 1987).  
However, there are other difficult times, such as adolescence, where receiving strong family 
support and positive reinforcement is central to maintaining good adhesion to the different 
treatments that have to meet the needs of these patients. The stresses between parents and 
children, and poor relationships between parents, are associated with low compliance and 
could have an adverse impact on the disease and health status of children with CF (Dziuban 
et al., 2010; Eddy et al., 1998; Foster et al., 2001; Smith et al., 2010).  
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4.4 Types of treatment 
There is wide agreement in the literature over the differences in adherence to the different 
components of the treatment of patients with CF. While the adherence to antibiotic therapy 
(80-95%) and intake of enzymes (65-90%) is high, we cannot say the same for habitual 
physiotherapy, exercise and the taking of vitamins and nutritional supplements, for which 
compliance is found to be about 40-55%. The high compliance found in relation to certain 
aspects of the treatment of patients with CF probably reflects the short-term benefit 
associated with a given treatment or else any immediate unpleasant symptoms which may 
result from non-compliance. An example of this would be the appearance of steatorrhea as a 
consequence of ending the intake of pancreatic enzymes in patients with exocrine pancreatic 
insufficiency. (Abbott et al., 1994; Conway et al., 1996; Daniels et al., 2011; McNamara et al., 
2009). 
4.5 Age 
Treatment adherence tends to decrease with age. Younger children show greater 
compliance, perhaps because during this time the responsibility for treatment lies with their 
parents. However, later on during adolescence, adherence decreases when the patient takes 
responsibility for their own treatment (Bucks et al., 2009; Dziuban et al., 2010; Gudas et al., 
1991; Zindani et al., 2006). 
The overall compliance of adolescents with CF is around 50%. Several factors, such as the 
family environment, staff perceptions about their illness, shame of displaying their problem 
in front of friends, and their relationship with their doctor are all classically associated with 
compliance, which is difficult to predict at this age due to the multiple factors involved 
(Michaud et al., 1991). All these factors occur at the time when the adolescent is transferred 
to the adult specialist (Kettler et al., 2002), and many patients experience suspicion and 
insecurity which also often tends to affect adherence. 
In chronic diseases, the normal behaviour of denial and a reduction of anxiety tend to 
increase with age in facilitating emotional adjustment in adulthood. So, while these attitudes 
improve the mental health of these patients they also often negatively affect their adherence 
(Lask, 1994). 
4.6 Epidemiological factors  
Demographic factors such as sex, level of educational, knowledge of the disease, 
socioeconomic status and occupation, and clinical factors such as the age of diagnosis and 
the frequency of clinical visits, have all been evaluated as possible predictors of adherence in 
CF cases, and have met with conflicting results (Abbott et al., 1994, 1996, 2001; Dziuban et 
al., 2010; Gudas et al., 1991; Oerman et al., 2000). 
4.7 Ways of coping with the disease  
Psychological factors are beginning to emerge as strong predictors of adherence. Classically, it 
was said that the incidence of mental health disorders in people with CF is recognisably 
similar to that of the general population. However, high levels of stress are common and 
require recognition and attention (Abbott et al., 2001; Dziuban et al., 2010; Kettler et al., 2002). 
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A large percentage of patients with CF and their parents reported elevated symptoms of 
depression. In a recent study, rates of depressive symptoms were elevated in children with 
CF and their parents (29% for children, 35% for mothers and 23% for fathers). In addition, 
child depressive symptoms were significantly associated with lower rates of adherence to 
airway clearance (Smith et al., 2010). 
Moise claims that there are lower levels of psychological distress and better adjustment in 
patients who use avoidance as a way of coping with illness, and those who use more direct 
methods and are positive (Moise et al., 1987). 
It is well-documented that poor psychological well-being can influence a detrimental 
physiological function and a disease’s progression, morbidity and mortality (Abbott et al., 2001). 
Perhaps it should be admitted that a degree of non-compliance is normal in these patients.  
Concern about their illness and the perception that they have little personal control over its 
course has been shown to be a facilitator of adherence. The way of coping with CF has a 
potential influence on the direction and course of their disease. In particular, denial has been 
associated with rebellion and persistent non-compliance, while the adopting of an attitude 
of optimism and hope is associated with greater compliance (Abbott et al., 1996, 2001; 
Dziuban et al., 2010). 
Currently, there is a major dilemma amongst health professionals with regard to promoting 
good mental health, whether they should allow denial and avoidance strategies for the 
patient to cope with the disease, or else whether they should promote compliance, which is 
dependent upon the recognition of the disease and the need for treatment. 
5. Treatment compliance in children and adults with CF 
The irregular adherence to treatment of patients with CF can alter the course of their illness. 
There are a number of important consequences of a failure to comply in treating CF, namely: 
deaths from cardiovascular diseases and infections, hospital admissions, increased visits, 
additional diagnostic testing requirements, additional alternative or unnecessary treatments, 
the home storage of medications and increased health spending. Knowledge of these aspects 
which motivate a patient in meeting certain treatments, and the discovery of the reasons 
given to justify the failure of others, can help the physician to promote adherence among 
their patients and influence the course of their disease. 
In 2008, we published a study designed to determine treatment compliance and how it was 
perceived by patients, parents and by a team of specialists in CF. We also analysed the 
relative importance given to each of the prescribed treatments and the reasons that were 
given for non-adherence, and we investigated the possible predictors of therapeutic 
compliance. We also looked at the reasons for non-adherence, so as to determine possible 
predictors of therapeutic compliance (Arias-Llorente et al., 2008).  
5.1 Patients and methods 
5.1.1 Patients 
Thirty-four CF patients controlled by the outpatient CF clinic of the University Central 
Hospital of Asturias and which attended periodic revisions (one each trimester) participated 
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in the study. Up until the age of 14 they are controlled by paediatric gastroenterologists and 
pneumologists and by an adult specialist from that age on. 
5.1.2 Study protocol 
Data was collected by reviewing the clinical histories of the patients and it included  
epidemiologic data (age, gender, age at the diagnosis of CF, the timing of the evolution of 
the disease and CFTR mutation), a respiratory evaluation (the treatment received at the 
time of the interview, spirometric values, Bhalla score, lung transplantation) and a 
digestive evaluation (body mass index (BMI), nutritional index (NI), blood levels of 
alkaline phosphatase, transaminases, gamma-glutamyl transpeptidase, fat soluble 
vitamins, folic acid, albumin,  β-carotene, faecal elastase, and immunoreactive trypsin, 72-
hour faecal fat) and global evaluation (associated co-morbidities, Shwachman-Kulczycki 
score). 
5.1.3 Questionnaire 
A self-administered questionnaire was given to each patient when attending a routine visit 
to be answered in the clinic. Patients older than 12 years completed the questionnaire 
themselves, while it was filled out by the parents of younger patients. The questionnaire 
included four different subsets of questions, one for each of the different treatments usually 
given to CF patients, namely: physiotherapy, respiratory medication (including DNase, 
antibiotics and inhaled corticosteriods), digestive medication (including pancreatic enzymes, 
vitamins, deoxycholic acid and antacids) and nutritional supplements. 
For each subset of therapeutic options, the CF patients were asked multiple questions on 
treatment compliance, the frequency of treatment, the importance attached to the treatment, 
their personal opinion about their own treatment compliance and the reasons given for non-
compliance. At the end of the questionnaire, the CF patients score (from 0 to 100%) their 
global therapeutic compliance, considering all the treatments received. 
According to the score obtained by the questionnaire, patients were then grouped according 
to their compliance or non-compliance for each of the therapeutic options and globally.  
In addition, the paediatric and adult gastroenterologists, pneumologists and nurses of the 
CF clinic were also asked to subjectively classify the treatment compliance of the CF patients 
in terms of compliance and non-compliance. 
5.2 Results 
Thirty-four CF patients (21 of which were female) with an age range of 1.6 to 40.6 years 
(mean 14.5) were included in the study. Fourteen patients were under 10 years of age, 11 
between 10 and 20, and 9 were older than 20. The average time of the evolution of the 
disease was 12.2 years (range from 1.3 to 40.6). 
5.2.1 Adherence for each type of treatment 
At the time of the study the average number of digestive and respiratory medications to be 
taken by the patients were 3.5 (range 0 to 7) and 4.5 (range 1 to 9) respectively.  
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Treatment compliance was greater for digestive (88.2%) and respiratory medication 
(61.8%), compared to physiotherapy (41.2%) and nutritional supplements (59%). This 
data is shown in Table 1, as well as that extracted from the views of the health 
professionals with regard to adherence of the patients to each type of treatment. The 
questionnaire results show a global compliance of 59%, whereby only 56% were 
compliant according to the opinion of the clinicians. Moreover, when the patient was 
directly asked, at the end of the questionnaire, to indicate their adherence to the therapy 
in their opinion, the treatment compliance was higher both for each type of treatment 
and globally. 
 QUESTIONNAIRE SPECIALISTS PATIENTS 
Physiotherapy 
Respiratory 
Nutritional 
Digestive 
Global 
41.2% 
61.8% 
59% 
88.2% 
59% 
35.3% 
59% 
56% 
70.4% 
56% 
62.% 
75.8% 
77.7% 
91.2% 
84.8% 
Table 1. The percentage of therapeutic adherence for each type of treatment based upon a 
questionnaire and specialist opinions and the perception of patients. 
In conclusion, CF patients had a greater treatment adherence when prescribed digestive and 
respiratory medications as opposed to physiotherapy and nutritional supplements. 
5.2.2 Degree and frequency of compliance  
All of the CF patients take their digestive medications daily, although 64.7% admitted that 
they only consume pancreatic enzymes during principal meals and not during snacks. 50% 
of the CF patients indicated daily treatment compliance with respiratory medication and 
nutritional supplements. On the other hand, 14.7% only took their respiratory medications 
when they felt worse and 5.8% never took them, and nearly 30% of the patients said that 
they never consume their nutritional supplements.  
The data from our questionnaire about physiotherapy is quite remarkable. Only 38.2% 
admitted to practising physiotherapy daily, while nearly 45% of patients reported as having 
physiotherapy only when they felt worse, occasionally or else never.  
38,2%
17,6% 17,6%
6%
20,6%
0%
20%
40%
daily
 3-5 times/week
occasionally
when i feel worse
never
 
Fig. 1. Frequency of practice of physiotherapy (percentage of patients). 
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5.2.3 The importance given to different types of treatment and their impact on quality 
of life 
The importance attached by patients to each type of treatment (average scores between 1 
and 10): physiotherapy, 7.17; respiratory medication, 8; digestive, 9.4; nutritional support, 
6.2) influenced compliance, and the treatments with the highest score saw the best level of 
adherence. 
CF patients considered their digestive medication to be indispensable (94.1%) compared to 
respiratory medications, physiotherapy and nutritional supplements (70.6%, 59% and 44.1% 
respectively). 
Type of treatment effect on quality of life was evaluated by the CF patients, and Table 2 
shows the results of this evaluation. While 85.3% of the patients thought that digestive 
medications significantly improve their quality of life, half of the CF patients considered that 
physiotherapy plays little or no role on their perceived quality of life. 
 
 Much Enough Little Nothing 
Physiotherapy 35.2%(25–45) 17.6%(5–31) 17.6%(5–31) 29.4% (14–44) 
Respiratory 26.5% (11–41) 29.4% (14–44) 11.7% (3–28) 14.7% (3–27) 
Digestive 38.2% (20–52) 44.1% (27–61) 2.9% (0.08–17) 8.8% (2–27) 
Nutritional 11.7% (3–28) 38.2%  (20–52) 11.7% (3–28%) 14.7% (3–27) 
Table 2. The impact of treatments on quality of life of the patients (95% confidence interval 
limits in brackets). 
5.2.4 Satisfaction 
Patient satisfaction about their own treatment adherence was significantly higher for 
digestive medication, with 70.6 % of the CF patients considering that they were taking the 
correct dose of digestive medication, while only 8.8% considered that they should have been 
more compliant. By way of contrast, only 29.4% of the CF patients considered that they were 
practising as much physiotherapy as they needed, in comparison to 41.2% who thought that 
they should practise more frequently. 
5.2.5 Reasons for poor compliance 
The main reason given for not taking digestive medications was forgetfulness. However, the 
most repeated excuses for not complying with respiratory medication and nutritional 
supplements were the belief that they didn’t need the medications (11.7% and 14.7% 
respectively), together with a lack of time for respiratory medication (8.8%) and the 
unpleasant taste or texture for nutritional supplements (14.7%). 
The reasons given for not doing physiotherapy exercises included not having enough time 
(23.5%), not needing the treatment (20.6%) and substitution by other exercises (20.6%).  
Actually, the median time that our patients employ in practising physiotherapy is 
noticeably less than the ageing of sickness evolution (7.6 years vs. 12.2 years). A 
considerable number of patients believe that physiotherapy is not necessary after receiving 
lung transplantation. 
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 % patients 
Physiotherapy  
Not enough time 29.4% 
I don´t think need it, I feel well without treatment. 20.6% 
Exercise instead 20.6% 
I don´t believe that it does my any good 14.7% 
It interferes with my social life 11.8% 
Simply forget 8.8% 
Transplantation 5.9% 
Respiratory medication  
I don´t think need it 11.7% 
Not enough time 8.8% 
Only when I feel worse 8.8% 
It interferes with my social life 5.9% 
Simply forget 5.9% 
Exercise instead 2.9% 
Nutritional supplements  
I don´t think need it 14.7% 
I don´t like the taste or texture 14.7% 
Simply forget 8.8% 
I don´t believe in it 5.9% 
Table 3. The predominant reasons for poor compliance with different treatments (percentage 
of patients). 
5.2.6 Differences between compliant and non-compliant CF patients 
It was objectified that treatment adherence decreases with age. We have observed that 23.8% 
of patients younger than 15 years were non-compliant, while this percentage rose to 69.2% 
for those older than 15 years, up to 89% for those older than 20 years. Non-compliant 
patients were significantly older (the average age of compliant patients was 10.4 years; that 
of non-compliant patients was 20.5 years, p=0.008) and had a longer time of evolution for 
their disease (compliant 9.4 years; non-compliant 16.8 years, p = 0.025). In our study, we 
have observed that adherence to treatment decreases with the severity of the CF disease 
(Shwachman score compliant 83.2 vs. non-compliant 73.9 points, p = 0.048).  
No gender differences were observed. Moreover, compliant CF patients attached more 
importance to all of the different therapeutic options than non-compliant CF patients (Table 
4). Nutritional parameters were also analysed, and compliant CF patients displayed 
significantly higher albumin values than non-compliant patients. No differences were 
observed for any of the other biochemical factors studied. No age-adjusted differences were 
observed in BMI. No differences were observed for faecal fat, NI, and spirometric values. 
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COMPLIANT 
Mean (SD) 
NON-COMPLIANT 
Mean (SD) 
P 
Physiotherapy 9.5 (2) 5 (0.7) 0.000 
Respiratory 8.8 (1.5) 6.4 ( 3) 0.010 
Digestive 9.7 (0.7) 7 (1.7) 0.001 
Nutritional 8.6 (1.4) 4.3 (3.1) 0.000 
Table 4. The importance attached to different therapeutic options by CF patients on a scale 
from 1 to 10 points. 
5.3 Discussion 
identified as determinants of adherence to different treatments. At the time of our study, the 
average number of digestive and respiratory medications to be taken by patients was 3.5 
(range 0 to 7) and 4.5 (range 1 to 9) respectively. These medications numbered too many 
even when compared with other studies, where there are even lists with more than twenty 
different treatments (Marciel et al., 2010). The explanation for this difference may be that the 
average age of patients is greater where there is a more prolonged progression of the disease 
and a possibly more serious illness. Whilst – in our study – the average age of the patients 
was 14.5 years, the mean time of the evolution of the disease was 12.2 years, and 58.8% of 
the controlled patients in our unit presented a good global prognostic score according to the 
Shwachman–Kulczycki scale, and even 26.4% were qualified as excellent.  
If these treatments are added to the need for other medications for associated pathologies 
and daily physiotherapy practice, they can give us an idea of how complicated the treatment 
was and the time spent on it. Given the long duration and arduous nature of these regimens, 
the maintenance of good compliance over prolonged periods will be a difficult task for the 
specialist responsible. Moreover, there are many other factors which may influence a decline 
in adherence: the perception of the disease which the patient has at any time, their different 
ways of coping with the disease (which can change throughout life), family, economic or 
social problems, a lack of trust in the responsible physician, erroneous beliefs about the 
benefits of different treatments, etc. 
As such, the patients who were considered to be particularly compliant could also go 
through phases of declining adherence. For this reason, it is very important not to relax 
during the monitoring of these chronic patients and to be alert to any problems that may 
affect their adherence to their treatment (Duff & Latchford, 2010). During this time, the team 
of specialists should try to understand and motivate the patient. 
Accordingly, there are works that strive to determine not only the degree of compliance of 
these patients, but also its variation over time and the reasons for this. Using this type of 
information, it is possible to identify which aspects of the treatment can be improved and to 
work together with families so as to individualise treatments. For example, a study designed 
to determine adherence to nebulised antibiotics by monitoring the routine data downloads of 
an adaptive aerosol delivery nebuliser in children with CF found considerable variation in 
adherence, both between and within patients, and even over the course of the day (evening 
adherence was better than morning adherence). Treatment regimens were changed for 8/28 
patients, based upon the data on adherence obtained by this study (McNamara et al., 2009). 
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Treatment adherence in CF cases, as with many other chronic diseases, has been around 50% 
and has rarely exceeded 80% (Abbott et al., 1996; Conway et al., 1996; Daniels et al., 2011; 
Kettler et al., 2002; McNamara et al., 2009). According to the data obtained by the 
questionnaire score, overall treatment compliance with the CF group controlled in our unit 
was 59%. Also, patients were asked directly as to what their level of compliance was, it was 
much higher both overall and for each type of treatment. Indeed, half of the patients believe 
that they comply with the therapeutic indications made by the specialist by at least 90%, a 
better level of adherence than the indicated by the results obtained by the questionnaire score. 
The fact that patients tend to overestimate their adherence to treatment is usually reflected 
in the literature. By way of contrast, the opinion of health professionals suggests a generally 
lower level of adherence (Abbott et al., 2001; Conway et al., 1996; Daniels et al., 2011; Modi 
et al., 2006). Moreover, it is usually the case that the perception of the severity of the disease 
also differs between physician and patient. A recent study assessed the agreement between 
rates of adherence to prescribed nebulisers when measured by self-reports, clinician reports 
and electronic monitoring suitable for long-term use, and differences in adherence were 
found. Here, median self-reported adherence was 80% whilst median clinician reported 
adherence was down to 50%-60% (Daniels et al., 2011). This was also observed in our study, 
as adherence to treatment as assessed by the team of specialists was lower than both the 
overall and for each type of treatment. So, according to our data, only 70% of those patients 
who believed themselves to be compliant (according to the questionnaire results) are also 
considered to be so by their specialised doctors.  
However, self-reporting and clinician reporting of adherence does not provide accurate 
measurement of adherence when compared with more objective measurement methods.  In 
this case, adherence is usually less than as shown in the study mentioned above, where the 
level of adherence measured by nebuliser downloads was 36% (Daniels et al., 2011). 
We are aware that the results of our study are based on subjective data obtained after a 
personal interview with parents and/or patients, which are then contrasted with the opinions 
of the clinicians belonging to the CF unit. There are also studies that clearly show that clinical 
impressions are not accurate enough to determine the real therapeutic adherence of patients, 
and so it would be also convenient to use a more objective method (Marciel et al., 2010; Modi 
et al.; 2006; Shemesh et al., 2004). It has been mentioned that the level of adherence could vary 
according to the subjectivity of the method employed, such as with a personal questionnaire, 
even if the results are corrected with the opinions of the medical professionals or other 
objective measures, such as blood-serum levels, the urinary excretion of medications or their 
metabolites, or the monitoring of adherence with electronic recording devices or the 
dispensers of medications (Conway et al., 1996; Modi et al., 2006; Rand et al., 1992; Teichman et 
al., 2000). Nevertheless these methods have their own inconveniences. With regard to the drug 
levels in serum or urine, we must emphasise that they are invasive methods and they may 
only represent yet another test for patients, due to the multiple samples needed to check their 
compliance, in addition to the pharmacokinetic variations of the substance are to be studied. 
Regarding electronic monitoring, the data obtained only provides information about the use of 
a medication dispenser, but not about whether the patient is actually taking the medication 
removed from the dispenser; moreover, this type of monitoring remains too expensive. This 
could also limit other evaluations concerning such aspects as diet, exercise and physiotherapy 
(Kettler et al., 2002; Rand et al., 1992). 
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In addition to finding differences in treatment compliance according to the methods 
discussed above, there are many works that refer to differences in adherence to the different 
components of the treatment carried out by patients with CF. Traditionally, it is said that 
adherence is low – between 40% and 55% – to nutritional supplements and physiotherapy. 
Meanwhile, treatment compliance to pancreatic enzymes and respiratory antibiotics 
increases to between 75% and 90% (Abbott et al., 2001; Daniels et al., 2011; Kettler et al., 
2002; Modi et al., 2006). 
In our study, and with regard to the types of treatment, most patients performed digestive 
medication (88.2% of patients), followed by respiratory medication (61.8%). Meanwhile 59% 
of patients were considered compliant with respect to nutritional support whilst only 41.2% 
were compliant with physiotherapy. In our case, the number of patients who were 
compliant towards digestive medication is similar to the results shown elsewhere (Abbott et 
al., 1994, 1996, 2001; Daniels et al., 2011; Modi et al., 2006) as well as the fact that only a third 
of patients took pancreatic enzymes at every meal, including snacks (Michaud et al., 1991). 
However, the level of adherence to respiratory medication was less than in others studies, 
which is perhaps explained by the fact that we did not analyse specific compliance with 
every aspect of respiratory treatment. If we had taken into consideration the individual’s 
adherence to bronchodilators, antibiotics or inhaled corticosteroids, the adherence to 
treatment would probably have been greater.  
When we asked patients about the importance that they attach to the different types of 
treatment (on a scale from 1 to 10 points), the highest score was assigned to digestive 
medication (9.4 points), corresponding with the most valued treatment in terms of 
compliance and its impact on quality of life. As such, 85.3% of the patients thought that 
digestive medication significantly improved their quality of life. As described in previous 
publications, our patients displayed better compliance with those treatments that they 
believed to be more important (Abbott et al., 2001; Patterson et al., 1993) and to have more 
repercussions for their quality of life (Conway et al., 1996; Czjkowski et al., 1987). 
In accordance with the details above, the two types of treatments that most patients seemed 
to consider essential were digestive and respiratory medications (94.1% and 70.6% 
respectively). This idea, coupled with the higher compliance observed in these treatments, is 
collected in earlier studies and it may reflect the short-term benefits of these and the 
precocity of the appearance of unpleasant symptoms as a result of non-compliance (Abbott 
et al., 1994, 1996, 2001; Conway et al., 1996; Kettler et al., 2002). Thus, adherence to 
pancreatic enzyme typically is high in order to avoid steatorrhea and the main reason for 
not taking this medication is “forgotten” and only one person says no need to take it despite 
having malabsorption. 
At the opposite end are nutritional supplements and physiotherapy. It is of concern that 
uniquely 44.1% consider nutritional supplements to be an essential treatment in clear 
concordance to the main reason given for not taking nutritional supplements: “I don’t think 
I need it”. And finally, only 59% of the patients believe physiotherapy is an essential 
treatment, in clear opposition to what physicians think. In fact, the type of treatment which 
we found to reflect a greater discrepancy between the opinions of doctors and patients was 
physiotherapy. This way of thinking agrees with patients’ perception of their slight 
repercussions for their quality of life (half of the CF patients felt that physiotherapy played 
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little or no role in their treatment) and the different degrees of importance attached to 
physiotherapy by compliant and non-compliant patients (9.5 points vs. 5 points, p0.001). In 
this connection, the data of our questionnaire concerning physiotherapy is remarkable since 
the practise of physiotherapy was particularly deficient with regard to the number of 
subjects doing it and its frequency; however, this is also found in the literature (Abbott et al., 
1996; Bernard & Cohen, 2004; Passero et al., 1981). The number of patients who practised 
daily physiotherapy only reached 38.2%, similar to other results in CF clinics (Abbott et al., 
2001; Oerman et al., 2000), and 20% even say that they never practice physiotherapy. 
On the other hand, the beginning of physiotherapy should be instituted at the time of the 
diagnosis of CF, a finding which is not supported by the average time that our patients have 
been practising (mean ± SD: 7.6±6.1 years), which is strikingly lower than the average time 
of the disease (12.2±8.9 years).  
Therefore, the main reasons claimed for non-compliance are a lack of time, the erroneous 
belief that they don’t need it or that they can substitute them with other exercise. As such, 
the perception that there are no beneficial effects with the treatment is wholesale problem 
for physiotherapy (Bernard & Cohen, 2004; Conway et al., 1996; Czjkowski et al., 1987; 
Shemesh et al., 2004; Teichman et al., 2001), and it has been published as being substituted 
with exercise in 20% of cases, just as we found (20.6%).  
A particular time when there is a risk of a decrease in adherence occurs, typically, after lung 
transplantation. Accordingly, we must emphasise that half of our transplanted patients have 
given up physiotherapy techniques afterwards, giving this hopeful event as the very reason 
for their lack of adherence. Even if it is known that medical opinions obviously contrast with 
this attitude, there is a recognised decrease in their therapeutic fulfilment after a lung 
transplantation which continues over time. It may be that they experience a better sense of 
wellbeing and so could hypothesise that they didn’t need it anymore. At this time, it is 
essential to provide them with clear information and to take care in following up with 
adequate supervision so as to reorient and help them eradicate these erroneous beliefs 
(Foster et al., 2001; Lask, 1994; Kettler et al., 2002; Oerman et al., 2000; Teichman et al., 2000). 
Such beliefs about the benefits of and need for each type of treatment significantly influence 
in the treatment adherence.  
In terms of patient satisfaction about their own adherence, it should be noted that is 
noticeably higher with the digestive intake of medication, such that 70.6% think that they 
should take this type of medication and only 8.8% think they should take more. At the other 
extreme is physiotherapy, where only 29.4% of patients believe that they should practise 
physiotherapy at all and 41% think that they should do it more often. If we compare this 
data with those described in previous works, it confirms a trend (Abbott et al., 1994). This is 
to say that patients are more satisfied with their compliance with digestive or respiratory 
medication than with their practise of physiotherapy. It is a paradoxical result because, 
although very few are happy with the practise of physiotherapy, there are few who think 
that they should do it more often. 
There are several factors which should be taken into account as possible predictors of 
adherence in CF cases, with contradictory results: demographic data such as sex, age, level 
of education, knowledge of sickness, socio-economic status, socio-familial relations and 
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profession, as well as clinical factors such as age at diagnosis, the severity of the CF or the 
frequency of checkups at CF clinics (Bernard & Cohen 2004; Jaffe & Bush, 2001; Kettler et al., 
2002; Oerman et al., 2000; Passero et al., 1981; Zindani et al., 2006). Our study found a 
statistically significant difference both in terms of the average age of each patient group, 
(compliant at 10.4 years and non-compliant at 20.5 years) and the time of the evolution of 
the disease (compliant at 9.5 years and non-compliant at 16.8 years). The fact that adherence 
to treatment tends to diminish with age has also been mentioned in the earlier studies 
(Conway et al., 1996; Gudas et al., 1991). In childhood, a high level of compliance is 
frequently observed, which is probably explained due to the fact that during this period of 
life the responsibility lies with the parents (Battistini et al., 1998; Foster et al., 2001). Family 
cohesion and adequate social support have both been associated with better adherence to 
treatment (Eddy et al., 1998; Foster et al., 2001; Hamutcy et al., 2002; Teichman 20009). In 
addition, the ways of coping with the disease by the mechanisms of denial and avoidance – 
which have been described as negative predictors of adherence to treatment – tend to 
increase with age amongst these chronically ill patients as they facilitate their emotional 
adjustment into adulthood (Kettler et al., 2002; Lask, 1994). 
A special time when compliance with treatment tends to decrease significantly is during 
adolescence, as was also found in our study, whereby parents release their progeny. This 
notion is reflected repeatedly in the literature for years (Bernard & Cohen, 2004; Bucks et al., 
2009; Conway et al., 1996; Mc Laughlin et al., 2008; Passero et al., 1998). So, in a study done 
in Montreal University 20 years ago on compliance with treatment amongst adolescents 
affected by chronic illness, such as CF, it was concluded that there was a global adherence of 
50%; nevertheless only 11% of the subjects demonstrated the successful accomplishment of 
all of the therapeutic components (Michaud et al., 1991).  In another study at Michigan 
University several years later, it has been shown that there is a significant difference 
between those patients who are less than 12 years old and those who are over twelve year 
old with regard to the intake of liposoluble vitamins amongst CF patients (Jaffe & Bush, 
2001). 
Adolescence means that the patients are presented with several other challenges apart from 
their illness, such that all of a sudden they are supposed to take control of themselves; 
perhaps they are prone to diminish its importance, or perhaps they display a reluctance to 
chat with their peers about their ‘big’ problem, or perhaps, even, they adopt a “hide and 
run” policy. They apologise, arguing with such reasons as “it interferes with my social life,” 
“I don’t want my friends to know that I suffer from CF,” as we have confirmed. Another 
reason in the decrease in self-accomplishment could be the transfer from paediatricians to 
adult medical staff (McLaughlin et al., 2008; Michaud et al., 1991), since initially it could 
mean a degree of instability and lack of reliance that is traduced into less adherence. 
For all of these reasons, there is often a growing recognition of need for support for their 
transition into adult-oriented healthcare. There is significant variability in the transitional 
support provided to young adults with CF (Mc Laughlin et al., 2008; Scal & Ireland; 2005). 
The first problem is the age of transition, because while in many centres the transfer of care 
for CF occurs at a median age of 19 years, in other programs it has been reported that the 
introduction of the concept of transition takes place before the age of 15 years (Anderson 
2002). In our CF unit, up until the age of 14 (younger than 15 years) they are controlled by 
paediatric gastroenterologists and pneumologists, and by an adult specialist from that age 
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onwards. The second problem relates to the different methods of transition that have been 
used. Few programmes provide educational materials about transition to patients and 
families, and fewer than half provide a transition time-line or designate a specific team 
member to be responsible for the key elements of transition (Mc Laughlin et al., 2008; 
Marciel et al., 2010). 
With regard to the severity of the disease, as determined by the score on the Shwachman-
Kulczycki scale, significant differences were found between the compliant and non-
compliant groups. We have observed that adherence to treatment decreases with the 
severity of CF. Some authors explain this phenomenon by reasoning to a lack of positive 
reinforcement whereby patients do not note a beneficial effect with their adherence to 
treatment (Hamutcy et al., 2002). However, there are also other authors who describe the 
opposite, with results relating disease severity with adherence to treatment (Oerman et al., 
2000; Zindani et al., 2006). 
In summary, we can say that there are differences in the degree of compliance by these 
patients with the various components of the treatment carried out. There is greater 
adherence to digestive and respiratory medications than to physiotherapy and nutritional 
supplements. We found a decrease in adherence according to age, the longer the history of 
the disease and the greater its severity. In addition, the treatments which were evaluated by 
patients as most important and as having the greatest impact on their quality of life 
witnessed the most adherence. 
6. Conclusion 
We can conclude that the global compliance with treatment is similar to that of other works, 
with a tendency of patients to overestimate their accomplishments as compared with the 
opinions of clinical staff. There are differences in the level of adherence to the various 
treatments, and this is realised by these patients.  
Of all the treatments that patients carry out, it was felt that the treatment which had the 
greatest impact on their quality of life, that which most considered to be essential and with 
which they were personally the most satisfied, involved gastrointestinal medicaments. 
Nevertheless, the practise of physiotherapy was highly deficient with regard to the number 
of subjects performing it and the frequency with which they did it, influenced by the general 
belief that it does not make much difference and that it has little repercussion for their 
quality of life.  
We have confirmed a decrease in therapeutic adherence with age, the longer the duration of 
evolution and the severity of the illness. There was no influence from the gender of the 
patients, their nutritional parameters, or from the data on pulmonary function. The 
treatments mostly appreciated by the patients as most essential were coincident with a 
higher level of adherence, emphasising the need for careful and continuous information, 
and the modification of erroneous beliefs.  
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